January 31, 2024 08:03 AM ESTUpdated 10:26 AM

Biogen to halt sales and development of controversial Alzheimer's drug Aduhelm

Kyle LaHucik

Senior Reporter

Biogen will stop sales and development of its controversial Alzheimer’s drug Aduhelm, walking away from a drug that was approved against outside experts’ advice, led …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biogen to halt sales and development of controversial Alzheimer's drug Aduhelm

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Bio­gen to halt sales and de­vel­op­ment of con­tro­ver­sial Alzheimer's drug Aduhelm

Senior Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Biogen to halt sales and development of controversial Alzheimer's drug Aduhelm